Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis
Abstract The pathogenesis of doxorubicin-induced cardiomyopathy remains unclear. This study was carried out to test our hypothesis that ADAM17 aggravates cardiomyocyte apoptosis induced by doxorubicin and inhibition of ADAM17 may ameliorate doxorubicin-induced cardiomyopathy. C57BL/6J mice were intr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-10-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-024-01977-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850181518504230912 |
|---|---|
| author | Lin Xie Fei Xue Cheng Cheng Wenhai Sui Jie Zhang Linlin Meng Yue Lu Wenjing Xiong Peili Bu Feng Xu Xiao Yu Bo Xi Lin Zhong Jianmin Yang Cheng Zhang Yun Zhang |
| author_facet | Lin Xie Fei Xue Cheng Cheng Wenhai Sui Jie Zhang Linlin Meng Yue Lu Wenjing Xiong Peili Bu Feng Xu Xiao Yu Bo Xi Lin Zhong Jianmin Yang Cheng Zhang Yun Zhang |
| author_sort | Lin Xie |
| collection | DOAJ |
| description | Abstract The pathogenesis of doxorubicin-induced cardiomyopathy remains unclear. This study was carried out to test our hypothesis that ADAM17 aggravates cardiomyocyte apoptosis induced by doxorubicin and inhibition of ADAM17 may ameliorate doxorubicin-induced cardiomyopathy. C57BL/6J mice were intraperitoneally injected with a cumulative dose of doxorubicin to induce cardiomyopathy. Cardiomyocyte-specific ADAM17-knockout (A17α-MHCKO) and ADAM17-overexpressing (AAV9-oeA17) mice were generated. In addition, RNA sequencing of the heart tissues in different mouse groups and in vitro experiments in neonatal rat cardiomyocytes (NRCMs) receiving different treatment were performed. Mouse tumor models were constructed in A17fl/fl and A17α-MHCKO mice. In addition, cardiomyocyte-specific TRAF3-knockdown and TRAF3-overexpressing mice were generated. ADAM17 expression and activity were markedly upregulated in doxorubicin-treated mouse hearts and NRCMs. A17α-MHCKO mice showed less cardiomyocyte apoptosis induced by doxorubicin than A17fl/fl mice, and cardiomyocyte ADAM17 deficiency did not affect the anti-tumor effect of doxorubicin. In contrast, AAV9-oeA17 mice exhibited markedly aggravated cardiomyocyte apoptosis relative to AAV9-oeNC mice after doxorubicin treatment. Mechanistically, doxorubicin enhanced the expression of transcription factor C/EBPβ, leading to increased expression and activity of ADAM17 in cardiomyocyte, which enhanced TNF-α shedding and upregulated the expression of TRAF3. Increased TRAF3 promoted TAK1 autophosphorylation, resulting in activated MAPKs pathway and cardiomyocyte apoptosis. ADAM17 acted as a positive regulator of cardiomyocyte apoptosis and cardiac remodeling and dysfunction induced by doxorubicin by upregulating TRAF3/TAK1/MAPKs signaling. Thus, targeting ADAM17/TRAF3/TAK1/MAPKs signaling holds a promising potential for treating doxorubicin-induced cardiotoxicity. |
| format | Article |
| id | doaj-art-af98d78fa20e4ff48cc58502eab236c3 |
| institution | OA Journals |
| issn | 2059-3635 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj-art-af98d78fa20e4ff48cc58502eab236c32025-08-20T02:17:53ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352024-10-019112010.1038/s41392-024-01977-zCardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axisLin Xie0Fei Xue1Cheng Cheng2Wenhai Sui3Jie Zhang4Linlin Meng5Yue Lu6Wenjing Xiong7Peili Bu8Feng Xu9Xiao Yu10Bo Xi11Lin Zhong12Jianmin Yang13Cheng Zhang14Yun Zhang15State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityDepartment of Emergency Medicine, Chest Pain Center, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Qilu Hospital, Shandong UniversityKey Laboratory Experimental Teratology of the Ministry of Education, Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong UniversityDepartment of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong UniversityDepartment of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityState Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong UniversityAbstract The pathogenesis of doxorubicin-induced cardiomyopathy remains unclear. This study was carried out to test our hypothesis that ADAM17 aggravates cardiomyocyte apoptosis induced by doxorubicin and inhibition of ADAM17 may ameliorate doxorubicin-induced cardiomyopathy. C57BL/6J mice were intraperitoneally injected with a cumulative dose of doxorubicin to induce cardiomyopathy. Cardiomyocyte-specific ADAM17-knockout (A17α-MHCKO) and ADAM17-overexpressing (AAV9-oeA17) mice were generated. In addition, RNA sequencing of the heart tissues in different mouse groups and in vitro experiments in neonatal rat cardiomyocytes (NRCMs) receiving different treatment were performed. Mouse tumor models were constructed in A17fl/fl and A17α-MHCKO mice. In addition, cardiomyocyte-specific TRAF3-knockdown and TRAF3-overexpressing mice were generated. ADAM17 expression and activity were markedly upregulated in doxorubicin-treated mouse hearts and NRCMs. A17α-MHCKO mice showed less cardiomyocyte apoptosis induced by doxorubicin than A17fl/fl mice, and cardiomyocyte ADAM17 deficiency did not affect the anti-tumor effect of doxorubicin. In contrast, AAV9-oeA17 mice exhibited markedly aggravated cardiomyocyte apoptosis relative to AAV9-oeNC mice after doxorubicin treatment. Mechanistically, doxorubicin enhanced the expression of transcription factor C/EBPβ, leading to increased expression and activity of ADAM17 in cardiomyocyte, which enhanced TNF-α shedding and upregulated the expression of TRAF3. Increased TRAF3 promoted TAK1 autophosphorylation, resulting in activated MAPKs pathway and cardiomyocyte apoptosis. ADAM17 acted as a positive regulator of cardiomyocyte apoptosis and cardiac remodeling and dysfunction induced by doxorubicin by upregulating TRAF3/TAK1/MAPKs signaling. Thus, targeting ADAM17/TRAF3/TAK1/MAPKs signaling holds a promising potential for treating doxorubicin-induced cardiotoxicity.https://doi.org/10.1038/s41392-024-01977-z |
| spellingShingle | Lin Xie Fei Xue Cheng Cheng Wenhai Sui Jie Zhang Linlin Meng Yue Lu Wenjing Xiong Peili Bu Feng Xu Xiao Yu Bo Xi Lin Zhong Jianmin Yang Cheng Zhang Yun Zhang Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis Signal Transduction and Targeted Therapy |
| title | Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis |
| title_full | Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis |
| title_fullStr | Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis |
| title_full_unstemmed | Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis |
| title_short | Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis |
| title_sort | cardiomyocyte specific knockout of adam17 alleviates doxorubicin induced cardiomyopathy via inhibiting tnfα traf3 tak1 mapk axis |
| url | https://doi.org/10.1038/s41392-024-01977-z |
| work_keys_str_mv | AT linxie cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT feixue cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT chengcheng cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT wenhaisui cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT jiezhang cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT linlinmeng cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT yuelu cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT wenjingxiong cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT peilibu cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT fengxu cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT xiaoyu cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT boxi cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT linzhong cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT jianminyang cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT chengzhang cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis AT yunzhang cardiomyocytespecificknockoutofadam17alleviatesdoxorubicininducedcardiomyopathyviainhibitingtnfatraf3tak1mapkaxis |